Small intestine-permeable cyclic peptide-mediated enhancement of Fc-fusion protein absorption in mice.

Chikamatsu S, Sakaguchi K, Sasaki K, Ohtsuki S, Ito S

Journal of pharmaceutical sciences19 May 2026

PMID42162694DOI10.1016/j.xphs.2026.104335PepBankPUB-42162694

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, unmodified dulaglutide lowered blood glucose as effectively as intravenous dulaglutide-DNP.
In plain wordsIn mice, unmodified dulaglutide lowered blood sugar as effectively as the intravenous dulaglutide-DNP fusion.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBlood glucose lowering by unmodified dulaglutide
Study
mousen: not reported in source
Comparator
Intravenous dulaglutide-DNP
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In mice, intravenous dulaglutide-DNP lowered blood glucose levels as effectively as unmodified dulaglutide, suggesting that DNP peptide fusion did not impair the intrinsic pharmacological activity of dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We selected dulaglutide, a GLP-1 analog fused to an IgG4 Fc moiety, as a model Fc-fusion protein. We produced dulaglutide-DNP, featuring a cyclic DNP peptide fused to the C-terminus of each Fc chain, in Chinese hamster ovary cells.
Report a problemFND-4216269403

Studies that did not test the peptide alone7

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

02AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome
In mice, intravenous dulaglutide-DNP lowered blood glucose as effectively as unmodified dulaglutide.
In plain wordsIn mice, the intravenous dulaglutide-DNP fusion lowered blood sugar as effectively as unmodified dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBlood glucose lowering by intravenous dulaglutide-DNP
Study
mousen: not reported in source
Comparator
Unmodified dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In mice, intravenous dulaglutide-DNP lowered blood glucose levels as effectively as unmodified dulaglutide, suggesting that DNP peptide fusion did not impair the intrinsic pharmacological activity of dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We selected dulaglutide, a GLP-1 analog fused to an IgG4 Fc moiety, as a model Fc-fusion protein. We produced dulaglutide-DNP, featuring a cyclic DNP peptide fused to the C-terminus of each Fc chain, in Chinese hamster ovary cells.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4216269404
03AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Pharmacokinetics
In mice, intraintestinal dulaglutide-DNP entered the portal vein within 10 minutes.
In plain wordsIn mice, the dulaglutide-DNP fusion entered the portal vein within 10 minutes after intestinal administration.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePortal vein entry after intraintestinal dulaglutide-DNP
Study
mousen: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Portal vein entry time
10 min
within, after intraintestinal dulaglutide-DNP
Source sentences
Summary
Following intraintestinal administration, pharmacokinetic analysis revealed that dulaglutide-DNP rapidly entered the portal vein within 10 min and could be subsequently detected in the systemic circulation.
1 context sentence(design, population, supporting numbers)
Summary · context
We selected dulaglutide, a GLP-1 analog fused to an IgG4 Fc moiety, as a model Fc-fusion protein. We produced dulaglutide-DNP, featuring a cyclic DNP peptide fused to the C-terminus of each Fc chain, in Chinese hamster ovary cells.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4216269405
04AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Pharmacokinetics
In mice, intraintestinal dulaglutide-DNP was detected in systemic circulation after portal vein entry.
In plain wordsIn mice, the dulaglutide-DNP fusion reached general circulation after intestinal administration and portal vein entry.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSystemic detection after intraintestinal dulaglutide-DNP
Study
mousen: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Following intraintestinal administration, pharmacokinetic analysis revealed that dulaglutide-DNP rapidly entered the portal vein within 10 min and could be subsequently detected in the systemic circulation.
1 context sentence(design, population, supporting numbers)
Summary · context
We selected dulaglutide, a GLP-1 analog fused to an IgG4 Fc moiety, as a model Fc-fusion protein. We produced dulaglutide-DNP, featuring a cyclic DNP peptide fused to the C-terminus of each Fc chain, in Chinese hamster ovary cells.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4216269406
05AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome
In mice, intraintestinal dulaglutide-DNP significantly reduced blood glucose to 39.0% of baseline.
In plain wordsIn mice, the intestinally administered dulaglutide-DNP fusion reduced blood sugar to 39.0% of its starting level.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBlood glucose after intraintestinal dulaglutide-DNP
Study
mousen: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
Blood glucose
39 % of baseline
intraintestinal dulaglutide-DNP
Source sentences
Summary
Consistent with this, pharmacodynamic analysis demonstrated that intraintestinal dulaglutide-DNP administration significantly reduced blood glucose levels to 39.0 % of the baseline, corresponding to a pharmacological availability of 15.7 % relative to intravenous dulaglutide-DNP administration.
1 context sentence(design, population, supporting numbers)
Summary · context
We selected dulaglutide, a GLP-1 analog fused to an IgG4 Fc moiety, as a model Fc-fusion protein. We produced dulaglutide-DNP, featuring a cyclic DNP peptide fused to the C-terminus of each Fc chain, in Chinese hamster ovary cells.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4216269407
06AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Pharmacokinetics
In mice, intraintestinal dulaglutide-DNP had pharmacological availability of 15.7% relative to intravenous dulaglutide-DNP.
In plain wordsIn mice, the intestinal dulaglutide-DNP fusion had 15.7% pharmacological availability compared with the intravenous fusion.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePharmacological availability of intraintestinal dulaglutide-DNP
Study
mousen: not reported in source
Comparator
Intravenous dulaglutide-DNP
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Pharmacological availability
15.7%
intraintestinal relative to intravenous dulaglutide-DNP
Source sentences
Summary
Consistent with this, pharmacodynamic analysis demonstrated that intraintestinal dulaglutide-DNP administration significantly reduced blood glucose levels to 39.0 % of the baseline, corresponding to a pharmacological availability of 15.7 % relative to intravenous dulaglutide-DNP administration.
1 context sentence(design, population, supporting numbers)
Summary · context
We selected dulaglutide, a GLP-1 analog fused to an IgG4 Fc moiety, as a model Fc-fusion protein. We produced dulaglutide-DNP, featuring a cyclic DNP peptide fused to the C-terminus of each Fc chain, in Chinese hamster ovary cells.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4216269408
07LabNot a test of Dulaglutide (Trulicity) aloneIn vitro (cell-free)Other
In protein tests, dulaglutide-DNP retained structural integrity comparable to unmodified dulaglutide.
In plain wordsIn lab tests, the dulaglutide-DNP fusion retained structural integrity similar to unmodified dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeStructural integrity of dulaglutide-DNP
Study
n: not reported in source
Dulaglutide-DNP fusion protein
Comparator
Unmodified dulaglutide
Outcome group
Peptide structure and chemistry · Pharmacology
Source sentences
Summary
Dulaglutide-DNP retained structural integrity and FcRn-binding affinity comparable to those of unmodified dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We selected dulaglutide, a GLP-1 analog fused to an IgG4 Fc moiety, as a model Fc-fusion protein. We produced dulaglutide-DNP, featuring a cyclic DNP peptide fused to the C-terminus of each Fc chain, in Chinese hamster ovary cells.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4216269401
08LabNot a test of Dulaglutide (Trulicity) aloneIn vitro (cell-free)Activity measurement
In protein tests, dulaglutide-DNP retained FcRn-binding affinity comparable to unmodified dulaglutide.
In plain wordsIn lab tests, the dulaglutide-DNP fusion bound the FcRn receptor similarly to unmodified dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeFcRn-binding affinity of dulaglutide-DNP
Study
n: not reported in source
Dulaglutide-DNP fusion protein
Comparator
Unmodified dulaglutide
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Dulaglutide-DNP retained structural integrity and FcRn-binding affinity comparable to those of unmodified dulaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We selected dulaglutide, a GLP-1 analog fused to an IgG4 Fc moiety, as a model Fc-fusion protein. We produced dulaglutide-DNP, featuring a cyclic DNP peptide fused to the C-terminus of each Fc chain, in Chinese hamster ovary cells.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4216269402

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.